Collage of charts and graphs with replay icon overlaying the image

Q1 2022 Conference Call Replay

  • 4:30 pm

Listen to the replay of the Q1 2022 conference call

Quarterly Financial Results and Business Overview

The Nephros Q1 2022 conference call replay features Andy Astor, President and CEO of Nephros, as he discusses the first-quarter financial results and presents an overview of the business over the last three months. Additional insights presented by Wes Lobo, CCO of Nephros, covering the commercial perspective and outlook for the future.

Read the Q1 2022 press release as a complement to the conference call recording. An excerpt of the release is included below.

“Revenue in 2022 got off to a slow start in Q1. First quarters are typically impacted by the reduced frequency of outbreaks in colder months; this quarter we saw a seasonal contraction to our outbreak response business that was greater than anticipated,” said Andy Astor, President and Chief Executive Officer.

“While this result represents a decrease over the same period last year, we are encouraged by our growth in active customer sites, which increased 17% year over year to 1,276. We believe the number of active customer sites is a good proxy for the underlying health of our business and future growth potential.”

Mr. Astor continued, “In light of lower revenue and the higher than expected volatility of our recovery, we are withdrawing our 2022 revenue guidance to better reflect current market conditions. Our optimism for the year remains high, and we maintain that our current cash balances are expected to suffice for the foreseeable future. Looking ahead, we feel strongly that our strategic investments over the past six months have built the commercial and digital infrastructure necessary to better reach a wider customer base, continue strong growth within our active customer sites, and ultimately, achieve our expected revenue growth and profitability.” 

Collage of charts and graphs with blue replay icon overlaying the image
Play recording of the Nephros Q1 2022 Conference Call

Learn More About Nephros